At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...
CROWN ctDNA data link early lorlatinib progression to genomic complexity, TP53 and bypass pathways rather than new ALK ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
HBI-8000-303 evaluates the HDAC inhibitor HBI-8000 plus nivolumab in advanced melanoma, examining PFS, response, safety, and ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg ...
Celebrating 8 Community Members Elected to the National Academy of Medicine - The Mark Foundation for Cancer Research / ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
Two Worlds Cancer Collaboration Session on Global Palliative Care - London Global Cancer Week 2026 / cancer, health care, ...
Frontline Magrolimab Plus Azacitidine in Higher-Risk MDS / cancer, ENHANCE trial, Hematology, magrolimab, MDS, ...
Daraxonrasib Versus Chemotherapy in Metastatic Pancreatic Cancer – Additional Subgroup Analyses / cancer, cancer care, Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results